---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000103"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:02:43.745568+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA grants Type B meeting for Praxis's ulixacaltamide in Q4 2025

## Summary
- FDA granted a Type B meeting following review of Essential3 topline results for ulixacaltamide.
- Meeting to occur in Q4 2025; pre-NDA meeting request was previously disclosed.
- Corporate presentation updated and posted on investors.praxismedicines.com.
- No financial results or guidance changes included in this filing.

## SEC filing metadata
- accession: 0001689548-25-000103
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/0001689548-25-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/prax-20251020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000103
- JSON: https://secwatch.observer/filing/0001689548-25-000103.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.